Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on March 17, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure). Combined cash consideration ~$56.9M ($13.5M for StrataDx equity + $43.4M for Bako assets), both deals closed March 17, 2026.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Combined cash consideration ~$56.9M ($13.5M for StrataDx equity + $43.4M for Bako assets), both deals closed March 17, 2026
- APA covers dermatopathology, podiatric pathology, molecular diagnostics, and therapeutic products: direct bolt-on to Inform Diagnostics subsidiary
- Lease assumed for 29,099 sq ft lab/office in Alpharetta, GA at $15.54/sq ft annually (~$452K/yr base rent), running through July 2026 with 2% annual escalator
- Both purchase prices subject to post-closing adjustments; escrow accounts funded at closing to secure potential true-ups
- Acquisitions expand FLGT's diagnostics footprint in dermatopathology: a specialty segment with recurring lab volume and potential cross-sell into Fulgent's genomics platform
Item 7.01 · Regulation FD Disclosure
- Fulgent Genetics (FLGT) and Consonance Capital Partners announced dual transaction closings: PSA (Purchase and Sale Agreement) and APA (Asset Purchase Agreement)
- Joint closing signals completion of a significant asset transaction with Consonance, a healthcare-focused investment firm
- Press release dated March 17, 2026 attached as Exhibit 99.1: full deal terms and financial details contained there
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.